Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion Inc (ACON) delivers innovative diagnostic solutions for chronic low back pain through its Nociscan SaaS platform, combining MRS technology with AI-driven biomarker analysis. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical advancements, financial milestones, and strategic initiatives.
Access timely press releases covering FDA communications, peer-reviewed study results, and partnership announcements with leading medical institutions. Our curated collection includes earnings reports, technology updates, and market expansion developments critical for evaluating ACON's position in medical imaging innovation.
Bookmark this page for streamlined access to verified information about Nociscan's clinical adoption, intellectual property developments, and evidence-based research outcomes. Stay informed about ACON's progress in transforming spine diagnostics through objective, noninvasive solutions supported by proprietary signal processing algorithms.
Aclarion, a healthcare technology company focused on chronic low back pain, announced significant findings from a clinical trial involving 78 patients. The trial demonstrated an 85% success rate for surgeries targeting discs identified by Nociscan, marking a 22 percentage point improvement over treatments not aligned with Nociscan results (85% vs. 63%; p=0.07). Nociscan, an augmented intelligence platform, measures pain biomarkers without invasive procedures like discography. This two-year durability data, published in the European Spine Journal, emphasizes the platform's potential to aid physicians in optimizing treatment strategies. Aclarion plans to continue clinical trials to further validate these findings and present additional economic benefits at upcoming conferences.
Aclarion, Inc. (Nasdaq: ACON, ACONW) announced the appointment of Dr. Alpesh Patel as a key opinion leader (KOL) to enhance its chronic low back pain (CLBP) solution, Nociscan. This marks the eighth advisor in Aclarion's KOL program aimed at strengthening clinical evidence for US commercialization. Nociscan leverages biomarkers and augmented intelligence to assist physicians in identifying pain sources in lumbar discs. Dr. Patel's expertise in spine care is expected to drive significant insights for Aclarion while participating in SPINEWEEK 2023 from May 1-5, 2023.
Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology firm, is set to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference from February 21-24, 2023. Jeff Thramann, Executive Chairman, will present on February 21 at 11:30 AM ET. The conference will feature 37 top companies selected by qualified institutional investors. Aclarion leverages biomarkers and augmented intelligence to identify chronic low back pain and has developed Nociscan, a SaaS platform that helps physicians distinguish between painful and nonpainful discs. For more details, visit www.aclarion.com.
Aclarion, a healthcare tech company focusing on chronic low back pain (CLBP), announced its participation in the 2nd Annual Sonntag Spine Symposium on February 17, 2023. Aclarion's flagship product, Nociscan, is the first SaaS platform that objectively measures discogenic biomarkers to aid in diagnosing CLBP. This innovative tool helps distinguish between painful and nonpainful discs, providing critical insights for treatment strategies. With over 266 million people affected by generative spine disease globally, Nociscan aims to optimize clinical outcomes through enhanced decision support for physicians.
Aclarion, a healthcare technology company listed on Nasdaq under ACON and ACONW, has appointed Dr. Gregory Basil from the University of Miami as a key opinion leader. Dr. Basil, a renowned spine surgeon, aims to enhance clinical outcomes through Aclarion's innovative Nociscan platform, which identifies chronic low back pain sources via biomarkers. This SaaS solution allows physicians to differentiate between painful and nonpainful lumbar discs, offering critical insights for optimized treatment strategies. Dr. Basil is the seventh advisor to join Aclarion's clinical evidence team, reinforcing its commitment to improving patient care.
